2020
Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG)
Xu B, Barbieri AL, Bishop JA, Chiosea SI, Dogan S, Di Palma S, Faquin WC, Ghossein R, Hyrcza M, Jo VY, Lewis JS, Lozada JR, Michal M, Pareja FG, Perez-Ordonez B, Prasad ML, Purgina B, Reis-Filho JS, Scognamiglio T, Sebastiao APM, Seethala RR, Skálová A, Smith SM, Tekkeşin MS, Thompson LDR, Wasseman JK, Wenig BM, Weinreb I, Katabi N. Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). The American Journal Of Surgical Pathology 2020, 44: 545-552. PMID: 31917707, PMCID: PMC7437128, DOI: 10.1097/pas.0000000000001431.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorBiopsyCanadaDNA Mutational AnalysisEuropeGene FusionGenetic Predisposition to DiseaseHumansIn Situ Hybridization, FluorescenceMutationObserver VariationPredictive Value of TestsReal-Time Polymerase Chain ReactionReproducibility of ResultsSalivary Gland NeoplasmsUnited StatesConceptsPapillary architectureIndeterminate featuresPolymorphous adenocarcinomaConsensus diagnosisCribriform adenocarcinomaInterobserver agreementSalivary glandsFair interobserver agreementNeck pathologistHistologic diversityHistologic classificationMorphologic spectrumDiagnostic concordanceSolid patternMolecular alterationsAdenocarcinomaGlomeruloid structuresTumorsLevel of agreementHotspot mutationsClear nucleiModerate agreementExpert pathologistsSuch molecular eventsMolecular signatures
2018
Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology
Nicolson NG, Murtha TD, Dong W, Paulsson JO, Choi J, Barbieri AL, Brown TC, Kunstman JW, Larsson C, Prasad ML, Korah R, Lifton RP, Juhlin CC, Carling T. Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2640-2650. PMID: 29726952, DOI: 10.1210/jc.2018-00277.Peer-Reviewed Original ResearchConceptsFollicular thyroid carcinomaThyroid carcinomaMutation burdenWorse disease-specific survivalDisease-specific survivalDifferent histopathological subtypesWorld Health Organization guidelinesSomatic mutationsNonsynonymous somatic mutationsHealth Organization guidelinesTotal mutation burdenIndependent predictorsWorse prognosisHistopathological subtypesPatient outcomesHistopathological classificationInvasive subtypesClinicopathologic parametersMutational burdenSurvival analysisSomatic copy number alterationsCopy number alterationsSubtypesOrganization guidelinesMore subclones
2017
Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon
Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Tuttle RM, Katabi N, Ghossein RA. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Human Pathology 2017, 65: 133-139. PMID: 28552827, PMCID: PMC5571865, DOI: 10.1016/j.humpath.2017.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaCarcinoma, PapillaryCell DifferentiationDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedMutationNeoplasm GradingNeoplasms, Unknown PrimaryPhenotypeProto-Oncogene Proteins B-rafRetrospective StudiesThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsConceptsPapillary thyroid carcinomaIdentifiable primary tumorThyroid carcinomaAnaplastic thyroid carcinomaMetastatic diseasePrimary tumorThyroid glandMetastatic papillary thyroid carcinomaEvidence of recurrenceMetastatic nodal diseaseMetastatic thyroid carcinomaTall cell variantBRAF V600E immunohistochemistryThyroid primaryNodal diseaseNeck compartmentDistant metastasisPathologic featuresRetrospective studyAnaplastic carcinomaUnknown causeMost tumorsCarcinomaPatientsThyroid tumorsPathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2016
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016, 122: 1097-1107. PMID: 26784937, DOI: 10.1002/cncr.29887.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCarcinomaCarcinoma, PapillaryChildDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansMaleMutationNew EnglandNuclear Pore Complex ProteinsOncogene Proteins, FusionProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-etsProto-Oncogene Proteins c-retReceptor, trkAReceptor, trkCRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionThyroid Cancer, PapillaryThyroid Neoplasms
2015
TERT promoter mutations are rare in parathyroid tumors
Haglund F, Juhlin CC, Brown T, Ghaderi M, Liu T, Stenman A, Dinets A, Prasad M, Korah R, Xu D, Carling T, Larsson C. TERT promoter mutations are rare in parathyroid tumors. Endocrine Related Cancer 2015, 22: l9-l11. PMID: 25876648, DOI: 10.1530/erc-15-0121.Peer-Reviewed Original Research
2014
Morphology predicts BRAFV600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study
Virk RK, Theoharis CG, Prasad A, Chhieng D, Prasad ML. Morphology predicts BRAFV600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Archiv 2014, 464: 435-442. PMID: 24549591, DOI: 10.1007/s00428-014-1552-3.Peer-Reviewed Original Research